High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma

Table 1

Patients characteristics at chemotherapy when starting ifosfamide.

Patients characteristics
Age, years
Median	33
Range	31–75
Histopathological diagnosis
Round cell myxoid liposarcoma (high grade)	7 (63%)
Classical myxoid liposarcoma (low grade)	4 (37%)
Metastatic disease at diagnosis	2 (18%)
Localized disease at diagnosis	9 (82%)
Adjuvant chemotherapy
Y	8 (73%)
N	3 (27%)
Adjuvant radiotherapy
Y	7 (64%)
N	4 (36%)
Number of sites involved
Median	2
Range	1–3
Local relapse	4 (36%)
Metastatic sites
Lung	8 (73%)
Abdominal cavity	7 (64%)
Bone	1 (9%)
Soft Tissue	1 (9%)
Number of prior chemotherapy regimens
0	1 (10%)
1	5 (45%)
2	3 (27%)
3	2 (18%)
Prior chemotherapy
Anthracycline ± Ifosfamide	11 (100%)
Trabectedin	3 (27%)
Pemetrexed	1 (10%)
Liposomal doxorubicin	1 (9%)
Unknown	2 (18%)
High-dose ifosfamide infusion
Elastomeric pump	11 (100%)
Number of ifosfamide courses
Median	3
Range	(2–7)